USA and United KingdomResearch and clinical trials
Experimental zorevunersen reduced seizures in Dravet syndrome in early-stage studies
A study published in a journal and reviewed by independent scientists. Even so, a single study is not conclusive; it needs to be replicated.
The drug is given into the spinal fluid through an injection in the lower back. Early-stage studies included 81 children aged 2 to 18. In those receiving the highest dose, convulsive seizures fell by more than half. Most side effects were mild or moderate. Two children died of sudden unexpected death in epilepsy, and one died of a feeding disorder.
What does it mean for patients and families?
There was no placebo group in these studies. The results need to be confirmed in a phase 3 trial. The drug is not yet approved.
Source
Scientific paper: Zorevunersen in Children and Adolescents with Dravet Syndrome. The New England Journal of Medicine, 2026. DOI: 10.1056/NEJMoa2506295 · PubMed 41780062
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Dravet syndrome
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.